课题基金 / 基金详情

Gene Therapy to Prevent Blindness in Patients with Congenital Aniridia

Gene Therapy to Prevent Blindness in Patients with Congenital Aniridia
基因疗法可预防先天性无虹膜患者失明
批准号：
382311
负责人：
Simpson Elizabeth M
金额：
$66.04万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-03-01 至 2023-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=382311&lang=en
关键词：
Content Analysis Humanized Mouse Models Of Aniridia In Vivo Raav Crispr Therapy In Vivo Raav Gene Augmentation Therapy Interview-Based Analysis Intrastromal Corneal Injection Minipromoters For Restricted Expression Mutation Specific And Independent

项目摘要

项目成果

Simpson Elizabeth M的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Aniridia is a rare eye disorder caused by half the normal amount of the protein paired box gene 6 (PAX6). It affects both sexes and is not known to be influenced by gender. Individuals with aniridia are typically born with low vision, and because there is
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene Therapy for PAX6-Aniridia: Focusing on the Eye
  • 批准号：
    310757
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2014
  • 负责人：
    Simpson Elizabeth M
  • 依托单位：
    University of British Columbia